Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.
Wurz RP, Allen JR, Allen JG, Amegadzie A, Chen N, Eshon J, Li K, Li X, Li Y, Manoni F, Medina JM, Navaratne P, Pettus LH, Rahimoff R, Stellwagen J, Tercenio Q, Weires N, Wigman B, Yamano M, Zhao W, Husemoen G, Leth-Petersen S, Bauer D, Frohn MJ, Mukhina OA, Boursier M, Vaish A, Poppe L, Mohr C, Chen YC, Diaz GJ, Gaida K, Hughes PE, Khetan J, Mohn D, Osgood T, Saiki AY, Rex K, Verma R, Wang P, Rui H, Yu J, Dahal UP, Li Y, Agarwal P, Wegesser T, Lanman BA.
Wurz RP, et al. Among authors: wang p.
J Med Chem. 2026 Jul 14. doi: 10.1021/acs.jmedchem.6c01325. Online ahead of print.
J Med Chem. 2026.
PMID: 42446418